Compare Enveric Biosciences Inc (ENVB) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Vanguard Information Technology Index Fund ETF trades at $127.19 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 25029.4× Enveric Biosciences Inc's market cap, and Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Vanguard Information Technology Index Fund ETF for 129 Days on average.
| ENVB | VGT | |
|---|---|---|
Market Cap | $6.80M | $170.20B |
Volume | 64,867 | 5,132,883 |
Sector | Health | — |
52-Week High | $10.80 | $129.79 |
52-Week Low | $1.27 | $83.59 |
Typical Hold Time | 14 Days | 129 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
VGT trades at $129.37, down 0.32% on the day, with a bullish technical signal driven by moving averages. The ETF recently reached a new 52-week high, reflecting strong momentum in the technology sector. Recent news highlights its historical performance and low expense ratio compared to peers, though RSI levels suggest potential overbought conditions.
The outlook remains positive given the tech sector's growth trajectory and institutional inflows, but risks include concentration in top holdings and sensitivity to AI sector volatility. Long-term investors may benefit from sector exposure, though near-term pullbacks are possible.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
